Intellia Therapeutics, Inc.NTLANASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-2.36%
↓ 123% below average
Average (39q)
10.17%
Historical baseline
Range
High:87.03%
Low:-32.23%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -2.36% |
| Q2 2025 | -10.51% |
| Q1 2025 | -7.23% |
| Q4 2024 | -5.27% |
| Q3 2024 | 10.55% |
| Q2 2024 | 2.08% |
| Q1 2024 | 0.32% |
| Q4 2023 | -4.15% |
| Q3 2023 | -1.37% |
| Q2 2023 | 18.70% |
| Q1 2023 | -2.92% |
| Q4 2022 | 3.50% |
| Q3 2022 | 7.15% |
| Q2 2022 | -32.23% |
| Q1 2022 | 87.03% |
| Q4 2021 | 17.65% |
| Q3 2021 | 2.72% |
| Q2 2021 | 49.92% |
| Q1 2021 | 2.73% |
| Q4 2020 | -3.84% |
| Q3 2020 | 5.26% |
| Q2 2020 | 9.01% |
| Q1 2020 | 9.20% |
| Q4 2019 | 15.33% |
| Q3 2019 | 8.06% |
| Q2 2019 | 7.39% |
| Q1 2019 | 19.03% |
| Q4 2018 | -14.28% |
| Q3 2018 | -0.98% |
| Q2 2018 | 4.33% |
| Q1 2018 | 6.25% |
| Q4 2017 | 21.10% |
| Q3 2017 | 12.31% |
| Q2 2017 | 15.89% |
| Q1 2017 | 18.53% |
| Q4 2016 | 44.14% |
| Q3 2016 | 5.90% |
| Q2 2016 | 42.07% |
| Q1 2016 | 19.43% |
| Q4 2015 | 26.52% |